文献速递膀胱癌与上尿路尿路上皮癌

局部晚期膀胱癌根治性膀胱切除术前放疗联合免疫治疗:前瞻性单臂多中心2期RACE-IT试验

Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).
PubMed 文献 · Eur Urol Oncol · 2026-02-25

该前瞻性多中心2期试验首次评估局部晚期膀胱尿路上皮癌患者在根治性膀胱切除术前接受纳武利尤单抗联合盆腔放疗的可行性、安全性和疗效。33例患者入组,31例可评估,完成治疗率87%(27/31),达到主要终点。病理缓解率ypT0 ypN0 cM0为39%,≤ypT1 ypN0 cM0为58%,≤ypT2 ypN0 cM0为74%。

要点

  • 新辅助放疗联合纳武利尤单抗在局部晚期膀胱癌中可行,完成治疗率87%。
  • ypT0 ypN0 cM0病理缓解率39%,≤ypT2 ypN0 cM0达74%。
  • 免疫相关不良事件发生率55%,3/4级不良事件33%,无治疗相关死亡。

核心结论

  • 该试验达到主要终点,首次证明局部晚期膀胱癌根治性膀胱切除术前新辅助放疗联合免疫治疗可行且安全。
  • 结果支持在随机对照 setting 中进一步研究该治疗模式。

研究设计与样本

  • 前瞻性、单臂、多中心2期试验,纳入局部晚期尿路上皮膀胱癌(cT3/4 cN0/N+ cM0)适合根治性膀胱切除但不宜或拒绝新辅助顺铂化疗的患者。
  • 患者接受四周期纳武利尤单抗240 mg每2周一次联合盆腔放疗最大剂量50.4 Gy,第11至15周行根治性膀胱切除加盆腔淋巴结清扫。
  • 共33例患者入组,主要终点和疗效分析纳入31例可评估患者。

主要发现

  • 主要终点完成治疗率87%(27/31),达到预设的>70%阈值。
  • 病理缓解率:ypT0 ypN0 cM0为39%,≤ypT1 ypN0 cM0为58%,≤ypT2 ypN0 cM0为74%。
  • 任何级别免疫相关不良事件发生率为55%,3/4级不良事件发生率为33%。
  • 无治疗相关死亡。

关键数值与推荐

  • 主要终点可行性定义为第15周末最低完成治疗率>70%,实际完成治疗率87%(27/31)。
  • 病理缓解率:ypT0 ypN0 cM0 39%,≤ypT1 ypN0 cM0 58%,≤ypT2 ypN0 cM0 74%。
  • 免疫相关不良事件任何级别55%,3/4级33%。

临床怎么用

  • 对于局部晚期膀胱癌且不宜或拒绝顺铂新辅助化疗的患者,新辅助放疗联合纳武利尤单抗可作为可行且安全的候选方案。
  • 治疗期间需关注免疫相关不良事件,3/4级事件发生率为33%。

局限性

  • 单臂设计,无对照组,结论需随机试验验证。
  • 样本量较小(33例入组,31例可评估)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Patients with locally advanced bladder cancer have a poor prognosis despite radical surgery. Early data on neoadjuvant immunotherapy are promising, with possible synergistic effects with radiation therapy. Therefore, this prospective multicenter phase 2 trial evaluated, for the first time, the feasibility, safety, and efficacy of neoadjuvant radioimmunotherapy before radical cystectomy. METHODS: Patients with locally advanced urothelial bladder cancer (cT3/4 cN0/N+ cM0) eligible for radical cystectomy but unfit or refusing neoadjuvant cisplatin-based chemotherapy were included in this prospective phase 2 trial. Patients received four cycles of nivolumab 240 mg every 2 wk combined with radiotherapy of the pelvis with a maximum dose of 50.4 Gy. Patients underwent radical cystectomy with pelvic lymphadenectomy between weeks 11 and 15. The primary endpoint was feasibility, defined as a minimum completed treatment rate of >70% at the end of week 15. KEY FINDINGS AND LIMITATIONS: Thirty-three patients were included. For the primary endpoint and efficacy analysis, 31 patients were eligible. The trial met its primary endpoint with a completed treatment rate of 87% (27/31). The pathological response rates were 39% with ypT0 ypN0 cM0, 58% with ≤ypT1 ypN0 cM0, and 74% with ≤ypT2 ypN0 cM0. Immune-related adverse events of all grades occurred in 55%, and grade 3/4 adverse events occurred in 33% of patients. There were no treatment-related deaths. CONCLUSIONS AND CLINICAL IMPLICATIONS: By meeting its primary endpoint, this trial demonstrated for the first time the feasibility and safety of neoadjuvant radioimmunotherapy prior to radical cystectomy in patients with locally advanced bladder cancer, warranting further investigation in a randomized setting.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Schmid SC, Jahnen M, Schiller K, et al. Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT). Eur Urol Oncol. 2026. PMID: 41748359. doi:10.1016/j.euo.2026.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。